United States-based Novadoz Pharmaceuticals announced on Wednesday that its corporate group entity, MSN Pharmaceuticals, has received approval from United States Food and Drug Administration (FDA) audit with zero observations for its new, 200,000 sq. ft. manufacturing facility in Piscataway, New Jersey.
The new facility is to produce high quality, generic pharmaceuticals to include both oral solids and liquids. It will include a modern lab and executive offices for both MSN Pharmaceuticals and Novadoz Pharmaceuticals.
The company has also received approval for generic Tiagabine (AB rated to Gabitril). Tiagabine 2mg, 4mg, 12mg & 16mg tablets are offered in bottles of 30. The product is indicated as adjunctive treatment for partial seizures in patients age 12-years and older.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US